ESTRO 35 Programme book

SUNDAY 1 MAY 2016

> Risk assessment of solid secondary malignancies in childhood Hodgkin Lymphoma after radiotherapy G. Zanella, M. Mascarin (Italy), A. Drigo, A. Pusiol, E.C. Fuga, F.M. Giugliano, A. Rosolen, M.G. Trovò

PV-0230

Symposium QA IN CLINICAL TRIALS: PROCESSES, IMPACT AND FUTURE PERSPECTIVES 10:45 - 11:45 | ROOM 2

Clinical trials traditionally form the basis on which evidence-based guidelines are made. Therefore the quality of the data should be closely monitored. Quality Assurance requirements for every step of the process of trial preparation, conduct and analysis will be presented and illustrated using several practical examples on how protocol deviations led to jeopardising significant investments in terms of manpower and money. Recent developments towards intensive international collaboration across different trial organisations will contribute to the streamlining of this process. Ultimately, effective QA management in clinical trials will be of benefit of all patients whether they participate or not in clinical trials. Chair: P. Poortmans (The Netherlands) Co-chair: N. Romeo (Italy)

10:45 > How effective is current clinical trial QA? Speaker: E. Miles (UK)

SP-0231

11:05 > How does QA impact on clinical outcomes? Speaker: D.C. Weber (Switzerland)

SP-0232

11:25 > What will we need for future RTQA in clinical trials? Speaker: C. Hurkmans (The Netherlands)

SP-0233

Proffered Papers RADIOBIOLOGY 3: NOVEL TARGETING APPROACHES IN COMBINATION

WITH RADIATION 10:45 - 11:45 | LONDRA Chair: G. Higgins (UK) Chair: M. Verheij (The Netherlands)

10:45 > Radiotherapy and L19-IL2: perfect match for an abscopal effect with long-lasting memory N.H. Rekers (The Netherlands), A. Yaromina, N.G. Lieuwes, R. Biemans, W.T.V. Germeraad, D. Neri, L. Dubois, P. Lambin 10:55 > Enhancing stereotactic radiation schedules using the vascular disrupting agent OXi4503 M.R. Horsman (Denmark), T.R. Wittenborn

OC-0234

OC-0235

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

95